The Centers for Medicare & Medicaid Services (CMS) announced another evaluation report of the Oncology Care Model (OCM) in January 2021, covering activities and results for performance periods 1 through 5 of 11. Precision’s Maureen Hennessey and Elizabeth Oyekan analyze what we’ve learned so far as they review the key findings and observations of performance periods 1 through 5.
We are happy to announce that PRECISIONeffect and PRECISIONvalue have made the list of MM&M’s Top 100 North American healthcare agencies of 2021!
Spurred by CMS’s decision to cover CAR-T cell therapies under Medicare, commercial payers are beginning to systematize approvals for CAR-T treatment as use of these breakthrough cancer therapies is beginning to ramp up. Precision’s Dan Danielson weighs in on factors driving authorizations now and what to expect as more CAR-T therapies are approved.
Why are some drugs that may be demonstrated as cost-effective not being recommended for reimbursement? PRECISIONadvisors Richard Macaulay and his co-author have published this influential study, uncovering that the NICE ICER thresholds have declined by 42.9% in real terms since 2004 (without accounting for inflation).
Despite the strengths and historical dominance of quantitative research in the health care domain, the importance of rigorous qualitative research as both a complement to, and a mechanism for, augmenting quantitative methods is increasingly being recognized and used across health-related disciplines.
In “Understanding the Impact of COVID-19 on Schizophrenia Population Health Management: A Mixed-Methods Study of Population Health Decision Makers”, PRECISIONheor authors Marlon Graf, Meaghan Roach, Priti Pednekar, and Jacki Chou sought to understand PHDMs’ perceptions of challenges, policies, and programs related to schizophrenia population health management, both generally and in the context of the COVID-19 pandemic.
China, the second largest pharmaceutical market in the world (valued at more than $150 billion), is experiencing a paradigm shift characterized by a booming economy, a growing middle class, and an increasingly aged population with rising disease rates. By reviewing recent changes to the Chinese pricing and market access landscape, PRECISIONadvisors’ Andrea Ong and Laura Montani discuss how manufacturers can capitalise on this booming market.
(more…)
A survey conducted by PRECISIONvalue of population health priorities among health systems and health plans since the onset of Covid-19 suggests that while mental health conditions have risen in priority, opioid use disorders have become alarmingly deprioritized. Precision’s Maureen Hennessey shares the survey data and offer observations and suggestions for opportunities for plans, delivery systems, and pharmaceutical manufacturers to address the mental health and substance use epidemics occurring within the COVID pandemic.
Every month, MassBio spotlights a member company and the great work they’re doing to advance the life sciences industry and support the patients they serve. In May, MassBio put the spotlight on Precision Value & Health with a Q&A with Precision’s Kelly Wilder.
The continued rise in health care spending is having a profound effect on the US economy and health care payers. Efforts have largely focused on transformation of our health system payment model, by moving from fee-for-service to value-based care, and reducing the costs of prescription drugs, as a means of reducing health care costs. Precision’s Elizabeth Oyekan and Andrew Cournoyer discuss why a multimodal, holistic approach is required to successfully tackle the issue of rising health care spending.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
